MDxHealth Successfully Raises ? 8.2 Million In Equity Issue
(Thomson Reuters ONE) -
DURHAM, NC, and LIEGE, BELGIUM - April 5, 2011 - MDxHealth SA (NYSE Euronext:
MDXH), a leading molecular diagnostics company in the field of personalized
cancer treatment, today announced that it has successfully raised approximately
? 8.2 million in gross proceeds through a private placement of new shares with
investors in various jurisdictions. Pursuant to the private placement, MDxHealth
will issue 5,436,713 new ordinary shares for an offer price of ? 1.50 per
share.
"We are delighted to have raised this additional funding from a broad range of
international investors who share our belief in the commercial potential of our
world leading DNA methylation platform," said Jan Groen, chief executive officer
of MDxHealth. "In combination with our existing cash position, these funds allow
us to accelerate the execution of our new business strategy and establish a U.S.
presence in the short term."
The net proceeds of the private placement will increase MDxHealth's financial
flexibility. They will be used to accelerate product development in line with
the new business strategy and to set up a CLIA laboratory and hire a sales and
marketing team in the US.
The payment and delivery of the new shares is expected to take place on April
8, 2011, at which date the new shares are also expected to be admitted to
listing, subject to the approval and publication of a listing prospectus. The
new shares will be fungible with the existing shares on NYSE Euronext.
Immediately after the closing of the private placement, MDxHealth's issued and
outstanding share capital will increase from 13,185,614 to 18,622,327 ordinary
shares.
Kempen & Co and Nomura Code Securities have acted as joint lead managers and
joint bookrunners and ING Belgium has acted as co-lead manager in the private
placement.
About MDxHealth
MDxHealth is a leading molecular diagnostics company that develops and
commercializes oncology-based molecular diagnostic testing for personalized
medicine. The company's tests are based on proprietary gene methylation
technology and assist physicians with the diagnosis of cancer, prognosis of
recurrence risk, and prediction of response to a specific therapy. MDxHealth
collaborates with leading cancer research center such as Johns Hopkins
University and Memorial Sloan Kettering, and major European academic medical
centers. The company has a number of commercial and collaborative partnerships
with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche,
Merck Serono, Pfizer, and other industry leaders. More information can be found
on the Company website:www.mdxhealth.com or on twitter at the following address
: www.twitter.com/mdxhealth.
For more information:
Dr. Jan Groen, CEO Hans Herklots
MDxHealth Capricorn One
+32 4 364 20 70 +41 79 598 7149
Important information about forward-looking statements
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation.
Important notice
This press release does not constitute an offer to sell or the solicitation of
an offer to buy any securities of MDxHealth, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation or sale is not
permitted or to any person or entity to whom it is unlawful to make such offer,
solicitation or sale. This press release is not an offer of securities for sale
into the United States, Canada, Australia or Japan.
The new shares have not been and will not be registered under the United States
Securities Act of 1933, as amended (the "US Securities Act") and may not be
offered or sold in the United States absent registration or an exemption from
registration. The Company does not intend to register any portion of the placing
in the United States or to conduct a public offering of securities in the United
States.
2011-04-05 Result ENG:
http://hugin.info/137314/R/1503634/438557.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MdxHealth via Thomson Reuters ONE
[HUG#1503634]
Unternehmensinformation / Kurzprofil:
Datum: 05.04.2011 - 17:45 Uhr
Sprache: Deutsch
News-ID 53186
Anzahl Zeichen: 5923
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 198 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MDxHealth Successfully Raises ? 8.2 Million In Equity Issue"
steht unter der journalistisch-redaktionellen Verantwortung von
MdxHealth (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
